Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review

Naoki Shimada; Nobuhiro Ohno; Ryuji Tanosaki; Shigeo Fuji; Yuhko Suzuki; Koichiro Yuji; Kaoru Uchimaru; Arinobu Tojo

doi:10.2169/internalmedicine.56.7763

Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review

Naoki Shimada, Nobuhiro Ohno, Ryuji Tanosaki, Shigeo Fuji, Yuhko Suzuki, Koichiro Yuji, Kaoru Uchimaru, Arinobu Tojo

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year. We reviewed 12 reported cases of AML complicating ATL to better characterize this unusual disease. We should therefore include t-AML in the differential diagnosis when administering low-dose etoposide for ATL over a long period of time.

Original language	English
Pages (from-to)	1879-1884
Number of pages	6
Journal	Internal Medicine
Volume	56
Issue number	14
DOIs	https://doi.org/10.2169/internalmedicine.56.7763
Publication status	Published - 2017
Externally published	Yes

Keywords

ATL
Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
HTLV-1
t-AML

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.56.7763

Cite this

Shimada, N., Ohno, N., Tanosaki, R., Fuji, S., Suzuki, Y., Yuji, K., Uchimaru, K., & Tojo, A. (2017). Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review. Internal Medicine, 56(14), 1879-1884. https://doi.org/10.2169/internalmedicine.56.7763

Shimada, N, Ohno, N, Tanosaki, R, Fuji, S, Suzuki, Y, Yuji, K, Uchimaru, K & Tojo, A 2017, 'Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review', Internal Medicine, vol. 56, no. 14, pp. 1879-1884. https://doi.org/10.2169/internalmedicine.56.7763

@article{19b06a1e067b40d19f1d1f57f0100f7a,

title = "Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review",

abstract = "A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year. We reviewed 12 reported cases of AML complicating ATL to better characterize this unusual disease. We should therefore include t-AML in the differential diagnosis when administering low-dose etoposide for ATL over a long period of time.",

keywords = "ATL, Allogeneic hematopoietic stem cell transplantation (allo-HSCT), HTLV-1, t-AML",

author = "Naoki Shimada and Nobuhiro Ohno and Ryuji Tanosaki and Shigeo Fuji and Yuhko Suzuki and Koichiro Yuji and Kaoru Uchimaru and Arinobu Tojo",

note = "Funding Information: We are grateful to Dr. Koji Miyazaki of Kitasato University School of Medicine (Sagamihara, Japan), Dr. Kiyosumi Ochi, and Ms. Etsuko Nagai of The Institute of Medical Science, The University of Tokyo (Tokyo, Japan) for valuable assistance with the preparation of the manuscript. Publisher Copyright: {\textcopyright} 2017 The Japanese Society of Internal Medicine.",

year = "2017",

doi = "10.2169/internalmedicine.56.7763",

language = "English",

volume = "56",

pages = "1879--1884",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "14",

}

TY - JOUR

T1 - Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma

T2 - A case report and literature review

AU - Shimada, Naoki

AU - Ohno, Nobuhiro

AU - Tanosaki, Ryuji

AU - Fuji, Shigeo

AU - Suzuki, Yuhko

AU - Yuji, Koichiro

AU - Uchimaru, Kaoru

AU - Tojo, Arinobu

N1 - Funding Information: We are grateful to Dr. Koji Miyazaki of Kitasato University School of Medicine (Sagamihara, Japan), Dr. Kiyosumi Ochi, and Ms. Etsuko Nagai of The Institute of Medical Science, The University of Tokyo (Tokyo, Japan) for valuable assistance with the preparation of the manuscript. Publisher Copyright: © 2017 The Japanese Society of Internal Medicine.

PY - 2017

Y1 - 2017

N2 - A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year. We reviewed 12 reported cases of AML complicating ATL to better characterize this unusual disease. We should therefore include t-AML in the differential diagnosis when administering low-dose etoposide for ATL over a long period of time.

AB - A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year. We reviewed 12 reported cases of AML complicating ATL to better characterize this unusual disease. We should therefore include t-AML in the differential diagnosis when administering low-dose etoposide for ATL over a long period of time.

KW - ATL

KW - Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

KW - HTLV-1

KW - t-AML

UR - http://www.scopus.com/inward/record.url?scp=85024409078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024409078&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.56.7763

DO - 10.2169/internalmedicine.56.7763

M3 - Article

C2 - 28717086

AN - SCOPUS:85024409078

SN - 0918-2918

VL - 56

SP - 1879

EP - 1884

JO - Internal Medicine

JF - Internal Medicine

IS - 14

ER -

Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for chronic-type adult T-cell leukemia-lymphoma: A case report and literature review

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this